|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPANK1 |
Gene summary for GPANK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPANK1 | Gene ID | 7918 |
| Gene name | G-patch domain and ankyrin repeats 1 | |
| Gene Alias | ANKRD59 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024RCU2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7918 | GPANK1 | LZE8T | Human | Esophagus | ESCC | 1.15e-03 | 8.45e-02 | 0.067 |
| 7918 | GPANK1 | LZE20T | Human | Esophagus | ESCC | 3.33e-03 | 1.70e-01 | 0.0662 |
| 7918 | GPANK1 | LZE24T | Human | Esophagus | ESCC | 1.08e-09 | 1.64e-01 | 0.0596 |
| 7918 | GPANK1 | LZE6T | Human | Esophagus | ESCC | 5.78e-07 | 2.63e-01 | 0.0845 |
| 7918 | GPANK1 | P1T-E | Human | Esophagus | ESCC | 3.42e-09 | 4.15e-01 | 0.0875 |
| 7918 | GPANK1 | P2T-E | Human | Esophagus | ESCC | 1.69e-26 | 5.18e-01 | 0.1177 |
| 7918 | GPANK1 | P4T-E | Human | Esophagus | ESCC | 1.21e-17 | 4.00e-01 | 0.1323 |
| 7918 | GPANK1 | P5T-E | Human | Esophagus | ESCC | 1.38e-17 | 3.03e-01 | 0.1327 |
| 7918 | GPANK1 | P8T-E | Human | Esophagus | ESCC | 1.27e-09 | 1.33e-01 | 0.0889 |
| 7918 | GPANK1 | P9T-E | Human | Esophagus | ESCC | 9.40e-11 | 2.54e-01 | 0.1131 |
| 7918 | GPANK1 | P10T-E | Human | Esophagus | ESCC | 7.99e-13 | 2.00e-01 | 0.116 |
| 7918 | GPANK1 | P11T-E | Human | Esophagus | ESCC | 3.41e-10 | 3.41e-01 | 0.1426 |
| 7918 | GPANK1 | P12T-E | Human | Esophagus | ESCC | 1.07e-16 | 3.00e-01 | 0.1122 |
| 7918 | GPANK1 | P15T-E | Human | Esophagus | ESCC | 1.97e-15 | 2.46e-01 | 0.1149 |
| 7918 | GPANK1 | P16T-E | Human | Esophagus | ESCC | 1.71e-18 | 3.10e-01 | 0.1153 |
| 7918 | GPANK1 | P17T-E | Human | Esophagus | ESCC | 7.49e-12 | 3.39e-01 | 0.1278 |
| 7918 | GPANK1 | P20T-E | Human | Esophagus | ESCC | 8.14e-08 | 2.08e-01 | 0.1124 |
| 7918 | GPANK1 | P21T-E | Human | Esophagus | ESCC | 1.14e-16 | 2.19e-01 | 0.1617 |
| 7918 | GPANK1 | P22T-E | Human | Esophagus | ESCC | 2.39e-23 | 3.27e-01 | 0.1236 |
| 7918 | GPANK1 | P23T-E | Human | Esophagus | ESCC | 2.45e-14 | 2.88e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPANK1 | SNV | Missense_Mutation | c.622N>T | p.Asn208Tyr | p.N208Y | O95872 | protein_coding | deleterious(0.05) | probably_damaging(0.925) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPANK1 | insertion | Frame_Shift_Ins | novel | c.485_486insTTTTTTTTTTGAGACAAAGTCTCACTCA | p.Leu163PhefsTer21 | p.L163Ffs*21 | O95872 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| GPANK1 | SNV | Missense_Mutation | c.272G>A | p.Arg91Lys | p.R91K | O95872 | protein_coding | tolerated(0.94) | benign(0.018) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GPANK1 | SNV | Missense_Mutation | c.331G>A | p.Ala111Thr | p.A111T | O95872 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GPANK1 | SNV | Missense_Mutation | novel | c.769N>G | p.Ser257Gly | p.S257G | O95872 | protein_coding | deleterious(0.02) | possibly_damaging(0.514) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| GPANK1 | SNV | Missense_Mutation | rs774998575 | c.47N>A | p.Ser16Asn | p.S16N | O95872 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| GPANK1 | SNV | Missense_Mutation | c.979G>A | p.Ala327Thr | p.A327T | O95872 | protein_coding | tolerated(0.34) | benign(0) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GPANK1 | insertion | Frame_Shift_Ins | rs765697080 | c.800_801insG | p.Trp268LeufsTer12 | p.W268Lfs*12 | O95872 | protein_coding | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GPANK1 | SNV | Missense_Mutation | novel | c.262N>A | p.Ala88Thr | p.A88T | O95872 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPANK1 | SNV | Missense_Mutation | novel | c.692N>A | p.Arg231His | p.R231H | O95872 | protein_coding | tolerated(0.56) | benign(0) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |